Difference between revisions of "Neuroblastoma - null regimens"
Jump to navigation
Jump to search
(Created page with "<span id="BackToTop"></span> <div class="noprint" style="background-color:LightGray; position:fixed; bottom:2%; right:0.25%; padding-left:5px; padding-right:5px; margin: 15px;...") |
m |
||
| Line 6: | Line 6: | ||
{{TOC limit|limit=3}} | {{TOC limit|limit=3}} | ||
| + | =High-risk, consolidation after upfront induction= | ||
| + | ==Observation {{#subobject:d9be60|Regimen=1}}== | ||
| + | <div class="toccolours" style="background-color:#eeeeee"> | ||
| + | ===Regimen {{#subobject:54059a|Variant=1}}=== | ||
| + | {| class="wikitable sortable" style="width: 100%; text-align:center;" | ||
| + | !style="width: 20%"|Study | ||
| + | !style="width: 20%"|Dates of enrollment | ||
| + | !style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]] | ||
| + | !style="width: 20%"|Comparator | ||
| + | !style="width: 20%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]] | ||
| + | |- | ||
| + | |[https://doi.org/10.1056/NEJM199910143411601 Matthay et al. 1999] | ||
| + | |1991-1996 | ||
| + | |style="background-color:#1a9851"|Phase 3 (C) | ||
| + | |[[Neuroblastoma#Isotretinoin_monotherapy|Isotretinoin]] | ||
| + | | style="background-color:#fc8d59" |Seems to have inferior EFS (primary endpoint) | ||
| + | |- | ||
| + | |} | ||
| + | ''No further treatment.'' | ||
| + | <div class="toccolours" style="background-color:#cbd5e8"> | ||
| + | ====Preceding treatment==== | ||
| + | *Matthay et al. 1999: [[Regimen_classes#High-dose_chemotherapy_with_auto_HSCT|HDT with purged auto HSCT]] versus [[Neuroblastoma#Cisplatin.2C_Doxorubicin.2C_Etoposide_888|cisplatin, doxorubicin, etoposide]] consolidation | ||
| + | </div></div> | ||
| + | ===References=== | ||
| + | # Matthay KK, Villablanca JG, Seeger RC, Stram DO, Harris RE, Ramsay NK, Swift P, Shimada H, Black CT, Brodeur GM, Gerbing RB, Reynolds CP; Children's Cancer Group. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. N Engl J Med. 1999 Oct 14;341(16):1165-73. [https://doi.org/10.1056/NEJM199910143411601 link to original article] [https://pubmed.ncbi.nlm.nih.gov/10519894/ PubMed] | ||
[[Category:Neuroblastoma regimens]] | [[Category:Neuroblastoma regimens]] | ||
[[Category:Disease-specific pages]] | [[Category:Disease-specific pages]] | ||
[[Category:Null regimens]] | [[Category:Null regimens]] | ||
Latest revision as of 16:00, 29 July 2024
The purpose of this page is to provide references to "null therapy" such as placebo and observation. These references provide further insight into the historical development of the treatment landscape. See the main neuroblastoma page for regimens that include active anticancer treatment.
High-risk, consolidation after upfront induction
Observation
Regimen
| Study | Dates of enrollment | Evidence | Comparator | Comparative Efficacy |
|---|---|---|---|---|
| Matthay et al. 1999 | 1991-1996 | Phase 3 (C) | Isotretinoin | Seems to have inferior EFS (primary endpoint) |
No further treatment.
Preceding treatment
- Matthay et al. 1999: HDT with purged auto HSCT versus cisplatin, doxorubicin, etoposide consolidation
References
- Matthay KK, Villablanca JG, Seeger RC, Stram DO, Harris RE, Ramsay NK, Swift P, Shimada H, Black CT, Brodeur GM, Gerbing RB, Reynolds CP; Children's Cancer Group. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. N Engl J Med. 1999 Oct 14;341(16):1165-73. link to original article PubMed